XML 37 R26.htm IDEA: XBRL DOCUMENT v3.7.0.1
Corrections to Previously Issued Consolidated Financial Statements (Details) - USD ($)
2 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Sep. 30, 2015
Mar. 31, 2017
Mar. 31, 2016
Mar. 31, 2017
Mar. 31, 2016
Sep. 30, 2016
Jul. 21, 2015
Consolidated Balance Sheet              
Due to related party $ 22,517 $ 950,000   $ 950,000   $ 6,500,000  
Total Liabilities 369,103 1,029,160   1,029,160   6,556,470  
Additional paid-in capital 1,132,685 10,583,912   10,583,912   4,733,461  
Accumulated deficit (315,602) (11,720,409)   (11,720,409)   (11,323,401)  
Total equity (deficit) 633,357 (922,750)   (922,750)   (6,379,118) $ 897,001
Consolidated Statements of Operations and Comprehensive Loss              
Selling, general and administrative expenses 315,602 208,315 $ 108,732 393,503 $ 110,359 997,263  
Research and development expenses 25,150 6,500,000 50,348 10,000,000 10,000,000  
Net loss from operations (315,602) (236,841) (6,608,764) (377,227) (10,110,391) (10,997,295)  
Loss from continuing operations before income taxes (315,602) (255,841) (6,608,712) (396,178) (10,110,147) (11,006,963)  
Net Loss $ (315,602) $ (256,671) $ (6,608,712) $ (397,008) $ (10,110,147) $ (11,007,799)  
Basic and diluted loss per share $ 0.00 $ (0.00) $ (0.03) $ (0.00) $ (0.05) $ (0.06)  
Consolidated Statements of Cash Flow              
Net loss from continuing operations $ (315,602) $ (256,671) $ (6,608,712) $ (397,008) $ (10,110,147) $ (11,007,799)  
Issuance of common stock for compensation and recapitalization         1,295,324  
(Decrease) increase in due to related party 22,517     (650,000) 9,977,483 6,477,483  
Net cash used in operating activities (715)     $ (1,017,127) (428,849) (3,474,707)  
Previously Reported on Form 10K [Member]              
Consolidated Balance Sheet              
Due to related party        
Total Liabilities           56,470  
Additional paid-in capital           4,733,401  
Accumulated deficit     (425,749)   (425,749) (4,823,401)  
Total equity (deficit)           120,882  
Consolidated Statements of Operations and Comprehensive Loss              
Selling, general and administrative expenses           4,497,263  
Research and development expenses        
Net loss from operations           (4,497,295)  
Loss from continuing operations before income taxes           (4,506,963)  
Net Loss     $ (108,712)   $ (110,147) $ (4,507,799)  
Basic and diluted loss per share     $ 0.00   $ 0.00 $ 0.00  
Consolidated Statements of Cash Flow              
Net loss from continuing operations     $ (108,712)   $ (110,147) $ (4,507,799)  
Issuance of common stock for compensation and recapitalization           1,295,324  
(Decrease) increase in due to related party           (22,517)  
Net cash used in operating activities (517)            
Restated [Member]              
Consolidated Balance Sheet              
Due to related party     10,000,000   10,000,000 6,500,000  
Total Liabilities           6,556,470  
Additional paid-in capital           4,733,461  
Accumulated deficit     (10,425,749)   (10,425,749) (11,323,401)  
Total equity (deficit)           (6,379,118)  
Consolidated Statements of Operations and Comprehensive Loss              
Selling, general and administrative expenses           997,263  
Research and development expenses     6,500,000   10,000,000 10,000,000  
Net loss from operations           (10,997,295)  
Loss from continuing operations before income taxes           (11,006,963)  
Net Loss     $ (6,608,712)   $ (10,110,147) $ (11,007,799)  
Basic and diluted loss per share     $ (0.03)   $ (0.05) $ (0.06)  
Consolidated Statements of Cash Flow              
Net loss from continuing operations     $ (6,608,712)   $ (10,110,147) $ (11,007,799)  
Issuance of common stock for compensation and recapitalization           1,295,324  
(Decrease) increase in due to related party           6,477,483  
Net cash used in operating activities (715)            
Adjustments No.1 [Member]              
Consolidated Balance Sheet              
Due to related party           6,500,000  
Total Liabilities           6,500,000  
Additional paid-in capital            
Accumulated deficit           (6,500,000)  
Total equity (deficit)           (6,500,000)  
Consolidated Statements of Operations and Comprehensive Loss              
Selling, general and administrative expenses           (3,500,060)  
Research and development expenses           10,000,000  
Net loss from operations           (6,499,940)  
Loss from continuing operations before income taxes           (6,499,940)  
Net Loss           $ (6,499,940)  
Basic and diluted loss per share           $ (0.06)  
Consolidated Statements of Cash Flow              
Net loss from continuing operations           $ (6,499,940)  
Issuance of common stock for compensation and recapitalization           (60)  
(Decrease) increase in due to related party           6,500,000  
Net cash used in operating activities            
Adjustments No.2 [Member]              
Consolidated Balance Sheet              
Due to related party            
Total Liabilities            
Additional paid-in capital           60  
Accumulated deficit            
Total equity (deficit)            
Consolidated Statements of Operations and Comprehensive Loss              
Selling, general and administrative expenses           60  
Research and development expenses            
Net loss from operations           (60)  
Loss from continuing operations before income taxes           (60)  
Net Loss           $ (60)  
Basic and diluted loss per share           $ 0.00  
Consolidated Statements of Cash Flow              
Net loss from continuing operations           $ (60)  
Issuance of common stock for compensation and recapitalization           60  
(Decrease) increase in due to related party            
Net cash used in operating activities $ (198)